These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
230 related items for PubMed ID: 4845938
1. Anticipated revisions to the current good manufacturing practice regulations. Mitchell CM. Bull Parenter Drug Assoc; 1974; 28(3):146-51. PubMed ID: 4845938 [No Abstract] [Full Text] [Related]
2. Current good manufacturing practice regulations. Bumiller J. Bull Parenter Drug Assoc; 1971; 25(5):222-5. PubMed ID: 5094094 [No Abstract] [Full Text] [Related]
4. Drug safety: the viewpoint of the pharmaceutical manufacturing industry. Wigle WW. Can Med Assoc J; 1968 Feb 10; 98(6):314-7. PubMed ID: 5636099 [No Abstract] [Full Text] [Related]
5. Influence of compounding on sterility and stability of drugs. Hardee GE. J Am Vet Med Assoc; 1994 Jul 15; 205(2):224-5. PubMed ID: 7928582 [No Abstract] [Full Text] [Related]
6. A product standards form for new radipharmaceuticals. Warbick A. Am J Hosp Pharm; 1974 Feb 15; 31(2):165-6. PubMed ID: 4815850 [No Abstract] [Full Text] [Related]
7. Some interpretations of controversial sub-sections in the Current Good Manufacturing Practice regulations for drug products. Loftus BT. J Parenter Drug Assoc; 1979 Feb 15; 33(6):326-32. PubMed ID: 261583 [No Abstract] [Full Text] [Related]
8. [Suggestions and recommendations for standardization of the systemic "routine" control during the production of the pharmaceutical dosage forms and their manufacturing]. Bellentani L, Carugati E, Colombo A, Ingraffia P. Boll Chim Farm; 1971 Mar 15; 110(3):131-46 contd. PubMed ID: 5561774 [No Abstract] [Full Text] [Related]
9. [Proposals for the legal control of the testing and introduction of drugs based on a comparison of drug laws in other countries]. Burow W, Lüllmann H. Schriftenr Geb Off Gesundheitswes; 1971 Mar 15; 31():1-64. PubMed ID: 5153578 [No Abstract] [Full Text] [Related]
13. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Caudron JM, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J. Trop Med Int Health; 2008 Aug 15; 13(8):1062-72. PubMed ID: 18631318 [Abstract] [Full Text] [Related]
14. A proposed European pharmacopeia monograph for continuous cell lines derived drugs. Dorpema JW. Dev Biol Stand; 1989 Aug 15; 70():113-24. PubMed ID: 2759345 [No Abstract] [Full Text] [Related]
15. [Risks in the delivery of drugs from the point of manufacture to the patient. I. Risks in manufacturing and compounding]. Samková M, Solich J. Cesk Farm; 1981 Dec 15; 30(10):349-54. PubMed ID: 7332939 [No Abstract] [Full Text] [Related]
16. Role of packaging in ethylene oxide sterilization. Panella JA. Bull Parenter Drug Assoc; 1974 Dec 15; 28(4):188-96. PubMed ID: 4212326 [No Abstract] [Full Text] [Related]
17. Drug product quality. Exp Med Surg; 1971 Dec 15; 29(1):135-44. PubMed ID: 5147595 [No Abstract] [Full Text] [Related]
18. Drug impurities: problems and regulations. Pifferi G, Mannucci A. Boll Chim Farm; 1999 Nov 15; 138(10):500-7. PubMed ID: 10765465 [Abstract] [Full Text] [Related]
19. Improving drug quality through certification experience. Weiss PJ. Am J Pharm Sci Support Public Health; 1974 Nov 15; 146(3):86-90. PubMed ID: 4852375 [No Abstract] [Full Text] [Related]
20. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirtieth report. World Health Organ Tech Rep Ser; 1987 Nov 15; 748():1-50. PubMed ID: 3111103 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]